Dexverapamil: A clinical approach to circumvention of multidrug resistance William S. DaltonManfred Lehnert Preface Pages: R1 - R1
Dexverapamil to overcome epirubicin resistance in advanced breast cancer B. ThürlimannN. KrögerM. Lehnert Original Paper Pages: R3 - R6
Phase I/II trial of dexverapamil, epirubicin and granulocyte/macrophage-colony-stimulating factor in patients with advanced pancreatic adenocarcinoma W. ScheithauerG. KornekC. Tetzner Original Article Pages: R7 - R10
Dexverapamil to modulate vinblastine resistance in metastatic renal cell carcinoma G. H. MickischM. A. NoordzijF. H. Schröder Original Paper Pages: R11 - R16
Randomised trial of vindesine and etoposide ± dexverapamil in advanced non-small cell lung cancer: First results U. GatzemeierA. SchneiderJ. v. Pawel Original Paper Pages: R17 - R20
Dexverapamil as resistance modifier in acute myeloid leukaemia R. PirkerS. ZöchbauerK. Lechner Original Paper Pages: R21 - R24
Modulation of multidrug resistance by dexverapamil in EPOCH-refractory lymphomas Wyndham H. WilsonSusan E. BatesBruce A. Chabner Original Paper Pages: R25 - R29